Picture Source: Pictures of Getty
Today (6 February) were good for shareholders of Astrazeneca (Lese: Azn). This page FTSE 100The largest company is closed 5.9% high at 11.786P after dropping a strong set of earnings.
This helped to push the foot to 8,766, high record. The interest rates are also determined today, making borrowing costs to 4.5%. Many benefits may therefore come.
I added to my catch in Practime Giant in the morning in November where the stock was immersed under 10,000p. This follows the stories of other management, I was investigated in China, which I suspected regardless of five years from now. We also had news about that today.
Hard growth and increasing profits
In 2024, the achievor Currency jumped 21% annually to $ 54.1BN for fixed money. That before it was a guide for youthful youthful growth and better than expected analysts ($ 53.1.1BN).
The sale growth was strong across the board, with its oncology (up 24%) and breathing (24%) the breakdown that leads to the road. Cancer account about 41% of total sales.
Viewing regional, Europe (up 26% in regular exchange rates) and market rates outside China (32%) increased significantly. However its largest market, US, recorded by impressive 22% Revenue Forort in the past year.
In the line below, the money received for each shared (EPS) has spent 19% to $ 8.21, before prediction ($ 8.15), and pre-tax benefits is deposited for 38% to $ 8.7bn.
The CEO PASCAL SORIOT is set up: “This year notes a temporary starting, very rich in our company, an important step in our covenant 2030 a quarter of total $ 80bn by the end of the decade. ”
While the growth of understanding is expected to go slowly by 2025, things still look strong. The income has increased by high percentage of high numbers, with EPs increased by two percent. It would not be possible if those figures end up higher on this next year.
Finally, division was taken from 7% last year, even though the forecasting crop is simply 2.2%.
Deep Small drugs
In my number, astrazeneca had 14 Chlockbusk drugs in 2024, which means each one produced more than $ 1bn in year’s sales. But a handful of some of the others draws closer.
One reason I own shares is the deepest pipe of new treatment company and the potential blockbusts. Last year, he brought about nine times late and expects some of the seven new drug medicines this year.
This gives the company many guns to vaccine, but naturally some will miss the target. The failure of the timing of the timing of the timing of the timing of the timely, as it is a bad tool. Donald Trump’s health secretary, the main critic of the Pharma Robert F Kennedy, also is a wild card.
At that time, the international trading warfare caused by Trump tax rates can see astrazeneca dealt with a number of remuneration under China. Talking about her …
Drop in the sea
What about China at that time? Of course, the matter has to do with unpaid taxes on two cancer drugs. But the good news is that the company sees the penalty for this between $ 900K and $ 4,5m.
While obviously it is wrong to be in bad books with Chinese authorities, this number is smaller global potatoes in Global Pharma Giant Giant.
Like Sharelder, I’m happy with all I’ve read here. But I’ll wait for another DIP before buying other stocks.
Source link
